ND-AMB (Abionyx)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameND-AMB (Abionyx)
Drug Alias NameND-AMB (Cerenis Therapeutics)NanoDisk-amphotericin B (Cerenis Therapeutics)NanoDisk-amphotericin B (Lypro)ND-AMB (Lypro)
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics
Mechanisms of ActionErgosterol bindersCell membrane permeability enhancers
TargetsErgosterol
Therapy Area/IndicationsLeishmaniasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLypro Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLypro Biosciences IncAbionyx Pharma SA
Active IndicationsN/A
Inactive IndicationsLeishmaniasis

Other Information

ATC CodeN/A
Related LinksN/A